IPO update, page-1334

So 'early March' would be some date before the midpoint of March? Great to see Yacov delivers again.
Then again, by Yacov's calendar it's not January 2022 yet, because if it was, Guthy Renker would be already selling Prizmas.

Any chance that insiders/people in touch with Yacov can ask him this:
1) Does GMVD plan to pursue NMPA in China?
2) Why did they cease pursuing NMPA in 2020? (Especially when clinical trial data was final in Jan 2020.)
If there's one outcome that could re-rate this joke stock, it would be NMPA.
(Personally, I suspect the abandonment of NMPA, and China as a market, is behind Yacov's decision to delist from ASX. The prior explanation that the inspector died, thus requiring fresh trials, was beyond laughable. China isn't a one-horse town with one doctor with one key to the filing cabinet. China's entire ethos is that everyone is replaceable.)